SecBot SecBot
Biotech Drug Report Generated Aug 28, 2026

CASGEVY

CRSP·CRISPR Therapeutics AG
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched (FDA approval December 2023)
Why 4/10
CASGEVY is already FDA-approved and commercially launched with no pending regulatory decision (PDUFA) in the next ~12 months. The next catalysts are commercial execution (quarterly revenue updates) and pipeline progress, not hard binary events. As an approved drug driving a single-product company's thesis, it scores 4, the defining binary (FDA approval) has already passed.
Actionable Insight NEUTRAL

Watch quarterly CASGEVY revenue trends as the key value driver, Q3 2026 results (~Nov 2026) will show whether the 151% YoY growth rate is sustainable. The 19.4% short interest and 15.6 days to cover create squeeze potential on positive commercial surprises, but the lack of a near-term binary catalyst limits near-term trading conviction. The analyst mean target of $87.56 implies ~48% upside from current levels.

Price Chart

Loading chart...

Executive Summary

CASGEVY (exagamglogene autotemcel) is the first FDA-approved CRISPR/Cas9 gene-edited therapy, developed by CRISPR Therapeutics (CRSP, Nasdaq) in partnership with Vertex Pharmaceuticals. Approved in December 2023 for sickle cell disease and beta-thalassemia, and expanded in 2026 to children aged 2+, it is a one-time cell therapy that edits a patient's own blood stem cells to boost fetal hemoglobin. Q2 2026 revenue reached $76M (+151% YoY), showing accelerating commercial adoption. CRSP trades at ~$59 with a mean analyst target of $87.56 (48% upside), but carries ~19.4% short interest. The stock's value is heavily concentrated in CASGEVY royalties, with the pipeline still early-stage.

How It Works

CASGEVY is a one-time gene-edited cell therapy. A patient's own blood stem cells are removed, edited using CRISPR/Cas9 technology to boost fetal hemoglobin production (which compensates for defective adult hemoglobin), and infused back into the patient. This addresses the root cause of sickle cell disease and beta-thalassemia.

Trial Status

FDA-approved in December 2023 for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Expanded label in 2026 to include children aged 2 and older. CASGEVY is the first CRISPR-based gene-edited therapy approved by the FDA. It is being commercialized in partnership with Vertex Pharmaceuticals, which books 100% of global revenue and shares profits with CRISPR Therapeutics (CRSP receives ~40% of profits).

The Two-Sided Case

▲ Bull Case5
CASGEVY is the first-ever FDA-approved CRISPR-based therapy, a landmark scientific and commercial asset with no direct CRISPR-based competitor
Q2 2026 CASGEVY revenue reached $76M (+151% YoY), showing accelerating commercial adoption and growing patient uptake
FDA label expansion to children aged 2+ opens a meaningful additional patient population
Analyst consensus is bullish: 17 Buy/Strong Buy ratings, mean price target $87.56 (48% upside from ~$59), with a high target of $291
Short interest of ~19.4% of shares outstanding with ~15.6 days to cover creates potential for a short squeeze on positive news
▼ Bear Case5
CASGEVY is a complex, expensive cell therapy requiring bone marrow conditioning (chemotherapy), limiting patient willingness and physician adoption
Vertex Pharmaceuticals books all CASGEVY revenue; CRISPR's ~40% profit share is netted as collaboration expense, reducing top-line transparency
Competition from bluebird bio's Lyfgenia (approved gene therapy for SCD) and emerging alternatives could pressure market share
CRSP is still unprofitable (Q2 2026 net loss of $91.2M) and relies heavily on CASGEVY royalties, pipeline diversification is still early-stage
High short volume ratio (frequently >60% of daily volume) and a 19.4% short interest indicate persistent bearish positioning

Upcoming Catalysts

  • Continued commercial ramp and quarterly CASGEVY revenue updates (next: Q3 2026 earnings ~November 2026)
  • Potential label expansions or real-world evidence readouts
  • Pipeline progress on CTX131 (Phase 2 CAR-T) and in vivo/siRNA programs

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report

Sources · 2

Hover a chip for the title
1 globenewswire.com2 globenewswire.com